U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07258108) titled 'Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors' on Nov. 20.
Brief Summary: This is a Phase II single-arm study designed to evaluate the efficacy and safety of Lucanisatuzumab + Tagolisumab in 35 patients with PD-L1+ HR+/HER2- advanced breast cancer who failed prior CDK4/6 inhibitor therapy. The primary endpoint is the 6-month PFS rate. Treatment will continue until disease progression or intolerable toxicity, with periodic imaging assessments and survival follow-up.
Study Start Date: Nov. 21
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: Lucanisatuzumab plu...